NO930199L - Oligonukleotidanaloger, deres fremstilling og anvendelse - Google Patents

Oligonukleotidanaloger, deres fremstilling og anvendelse

Info

Publication number
NO930199L
NO930199L NO93930199A NO930199A NO930199L NO 930199 L NO930199 L NO 930199L NO 93930199 A NO93930199 A NO 93930199A NO 930199 A NO930199 A NO 930199A NO 930199 L NO930199 L NO 930199L
Authority
NO
Norway
Prior art keywords
aryl
alkyl
preparation
seh
alkoxy
Prior art date
Application number
NO93930199A
Other languages
English (en)
Other versions
NO930199D0 (no
NO308215B1 (no
Inventor
Eugen Uhlmann
Anuschirwan Peyman
Gerard O'malley
Matthias Helsberg
Irvin Winkler
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO930199D0 publication Critical patent/NO930199D0/no
Publication of NO930199L publication Critical patent/NO930199L/no
Publication of NO308215B1 publication Critical patent/NO308215B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
NO930199A 1992-01-22 1993-01-21 Oligonukleotidanaloger, deres anvendelse og farmasøytiske sammensetning inneholdende disse NO308215B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4201662 1992-01-22

Publications (3)

Publication Number Publication Date
NO930199D0 NO930199D0 (no) 1993-01-21
NO930199L true NO930199L (no) 1993-07-23
NO308215B1 NO308215B1 (no) 2000-08-14

Family

ID=6450030

Family Applications (1)

Application Number Title Priority Date Filing Date
NO930199A NO308215B1 (no) 1992-01-22 1993-01-21 Oligonukleotidanaloger, deres anvendelse og farmasøytiske sammensetning inneholdende disse

Country Status (17)

Country Link
EP (1) EP0552766B1 (no)
JP (1) JP3717081B2 (no)
KR (1) KR930016437A (no)
AT (1) ATE217880T1 (no)
AU (1) AU661365B2 (no)
CA (1) CA2087818C (no)
DE (1) DE59310285D1 (no)
DK (1) DK0552766T3 (no)
ES (1) ES2177532T3 (no)
FI (1) FI115214B (no)
HU (1) HU227794B1 (no)
IL (1) IL104461A (no)
NO (1) NO308215B1 (no)
NZ (1) NZ245720A (no)
PL (1) PL172257B1 (no)
PT (1) PT552766E (no)
ZA (1) ZA93422B (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5646261A (en) * 1992-01-22 1997-07-08 Hoechst Aktiengesellschaft 3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use
EP0593901B2 (de) 1992-09-24 2008-04-09 Sanofi-Aventis Deutschland GmbH Oligoribonucleotid- und Ribozym-Analoga mit terminalen 3'-3'-bzw.5'-5'-Verknüpfungen
EP0602524A1 (de) * 1992-12-15 1994-06-22 Hoechst Aktiengesellschaft Chemilumineszenzmarkierte Gensonden und ihre Verwendung in Gensondentesten
DE69402177T2 (de) * 1993-01-08 1997-06-26 Hybridon Inc Synthese von dimer-blöcken und ihre verwendung bei der zusammensetzung von oligonukleotiden
US6087491A (en) 1993-01-08 2000-07-11 Hybridon, Inc. Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks
ES2086997T3 (es) * 1993-01-25 1996-07-01 Hybridon Inc Oligonucleotido-alquilfosfonatos y -alquilfosfonotioatos.
CA2114355A1 (en) * 1993-01-29 1994-07-30 Hidehiko Furukawa Modified oligodeoxyribonucleotides, their preparation and their therapeutic use
US5532130A (en) * 1993-07-20 1996-07-02 Dyad Pharmaceutical Corporation Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides
DE4331670A1 (de) * 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
DE4338704A1 (de) 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
US6919441B2 (en) 1994-03-14 2005-07-19 Aventis Pharma Deutschland Gmbh Polyamide-oligonucleotide derivatives, their preparation and use
DE4408528A1 (de) * 1994-03-14 1995-09-28 Hoechst Ag Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung
HUT76094A (en) * 1994-03-18 1997-06-30 Lynx Therapeutics Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
US5726297A (en) * 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
DE4415370A1 (de) * 1994-05-02 1995-11-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
US5986076A (en) * 1994-05-11 1999-11-16 Trustees Of Boston University Photocleavable agents and conjugates for the detection and isolation of biomolecules
US5696248A (en) * 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives
DE4438918A1 (de) * 1994-11-04 1996-05-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
US6150510A (en) 1995-11-06 2000-11-21 Aventis Pharma Deutschland Gmbh Modified oligonucleotides, their preparation and their use
DE19502912A1 (de) 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
DE59607750D1 (de) * 1995-03-13 2001-10-31 Aventis Pharma Gmbh Phosphonomonoesternnukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
US6326487B1 (en) 1995-06-05 2001-12-04 Aventis Pharma Deutschland Gmbh 3 modified oligonucleotide derivatives
US5684143A (en) * 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US5859233A (en) * 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
GB9606158D0 (en) * 1996-03-23 1996-05-29 Ciba Geigy Ag Chemical compounds
EP0808898B1 (en) * 1996-05-24 2004-05-19 Aventis Pharma Deutschland GmbH Reagent and method for inhibition of N-ras expression
DE19627898A1 (de) * 1996-07-11 1998-01-15 Hoechst Ag Festphasensynthese von Oligonucleotiden
BR9809242A (pt) * 1997-05-05 2000-06-27 Hoechst Marion Russel Deutschl Nucleotìdeos anti-sentido modificados complementares a uma seção do gene ha-ras humano
AU9460898A (en) * 1997-10-14 1999-05-03 Sankyo Company Limited Modified oligodeoxyribonucleotides having tggg sequence
EP1004661A1 (de) 1998-11-11 2000-05-31 DALLI-WERKE WÄSCHE- und KÖRPERPFLEGE GmbH & Co. KG Verdichtetes Granulat, Herstellungsverfahren und Verwendung als Sprengmittel für gepresste Formkörper (2)
DE19935302A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Konjugate und Verfahren zu deren Herstellung sowie deren Verwendung zum Transport von Molekülen über biologische Membranen
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
DE10133915A1 (de) 2001-07-12 2003-02-06 Aventis Pharma Gmbh Neue Oligoribonucleotid-Derivate zur gezielten Hemmung der Genexpression
WO2005021749A1 (en) 2003-08-28 2005-03-10 Novartis Ag Interfering rna duplex having blunt-ends and 3’-modifications
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
CN102016036B (zh) 2008-02-11 2015-04-08 阿克赛医药公司 经修饰的RNAi多核苷酸及其用途
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
EP3336188B1 (en) 2008-09-22 2020-05-06 Phio Pharmaceuticals Corp. Reduced size self-delivering rnai compounds
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
RU2615143C2 (ru) 2010-03-24 2017-04-04 Адвирна Самодоставляющие PHKi соединения уменьшенного размера
IL265674B2 (en) 2010-03-24 2024-05-01 Phio Pharm Corp Rana disorder in cutaneous and fibrotic symptoms
CN106074591B (zh) 2010-03-24 2020-01-14 菲奥医药公司 眼部症候中的rna干扰
JP6772062B2 (ja) 2013-12-02 2020-10-21 フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． 癌の免疫療法
WO2015125845A1 (ja) * 2014-02-20 2015-08-27 塩野義製薬株式会社 含窒素非芳香族複素環を含む核酸のリン酸部位修飾
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
CN107073294A (zh) 2014-09-05 2017-08-18 阿克赛医药公司 使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法
WO2017007825A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
EP3862005A1 (en) 2015-07-06 2021-08-11 Phio Pharmaceuticals Corp. Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
US11021707B2 (en) 2015-10-19 2021-06-01 Phio Pharmaceuticals Corp. Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
KR20210018267A (ko) 2018-05-07 2021-02-17 알닐람 파마슈티칼스 인코포레이티드 간외 전달

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3239888A1 (de) * 1982-10-28 1984-05-03 Hubert Prof. Dr. 2000 Hamburg Köster Verfahren zur herstellung von oligonucleosidphosphonaten
US4739044A (en) * 1985-06-13 1988-04-19 Amgen Method for derivitization of polynucleotides
DE3751468T2 (de) * 1986-10-30 1996-02-29 Daicel Chem Verfahren zur herstellung von oligonukleotiden und verbindungen zur bildung hochmolekularer schutzgruppen.
US4816571A (en) * 1987-06-04 1989-03-28 Applied Biosystems, Inc. Chemical capping by phosphitylation during oligonucleotide synthesis
ATE269870T1 (de) * 1989-10-24 2004-07-15 Isis Pharmaceuticals Inc 2'-modifizierte oligonukleotide
US5210015A (en) * 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
GB9021625D0 (en) * 1990-10-04 1990-11-21 Ici Plc Synthesis of oligonucleotides

Also Published As

Publication number Publication date
KR930016437A (ko) 1993-08-26
AU3191093A (en) 1993-07-29
JPH05310779A (ja) 1993-11-22
ATE217880T1 (de) 2002-06-15
HU227794B1 (en) 2012-03-28
PL297515A1 (en) 1993-09-06
DE59310285D1 (de) 2002-06-27
PT552766E (pt) 2002-10-31
ES2177532T3 (es) 2002-12-16
JP3717081B2 (ja) 2005-11-16
EP0552766A3 (en) 1994-09-07
FI115214B (fi) 2005-03-31
EP0552766A2 (de) 1993-07-28
CA2087818C (en) 2007-07-10
NZ245720A (en) 1995-12-21
EP0552766B1 (de) 2002-05-22
HUT63173A (en) 1993-07-28
HU9300162D0 (en) 1993-04-28
FI930220A0 (fi) 1993-01-20
IL104461A (en) 2001-05-20
PL172257B1 (pl) 1997-08-29
IL104461A0 (en) 1993-05-13
NO930199D0 (no) 1993-01-21
NO308215B1 (no) 2000-08-14
ZA93422B (en) 1993-09-16
FI930220A (fi) 1993-07-23
DK0552766T3 (da) 2002-08-19
AU661365B2 (en) 1995-07-20
CA2087818A1 (en) 1993-07-23

Similar Documents

Publication Publication Date Title
NO930199D0 (no) Oligonukleotidanaloger, deres fremstilling og anvendelse
US5317098A (en) Non-radioisotope tagging of fragments
Sinha et al. β-Cyanoethyl N, N-dialkylamino/N-morpholinomonochloro phosphoamidites, new phosphitylating agents facilitating ease of deprotection and work-up of synthesized oligonucleotides
AU742241B2 (en) PNA and DNA conjugates and methods for preparation thereof
ATE242260T1 (de) Sulfonatfreie cyaninfarbstoffe zur markierung von nukleosiden und nukleotiden
ATE199725T1 (de) Synthetische katalytische oligonukleotide
DE69415343D1 (de) 2'-amido-und 2'-peptido-modifizierte oligonukleotide
ES2179080T3 (es) Derivados de poliamida-oligonucleotido, su preparacion y utilizacion.
DE60002989D1 (de) Verfahren zur herstellung von morpholinonukleotiden und verwendung derselben zur analyse und markierung von nukleinsäuresequenzen
ATE55109T1 (de) Chemisches verfahren zur herstellung von abkoemmlingen von oxamid.
EP0462224B1 (en) Sequencing nucleic acids using chemiluminescent detection
GB0016258D0 (en) Base analogues
DE69501705D1 (de) Verfahren zur Herstellung von optisch aktiven Piperazinderivaten und Zwischenprodukten für ihre Herstellung

Legal Events

Date Code Title Description
MK1K Patent expired